Cargando…
Medication adversely impacts visually-guided eye movements in Parkinson’s disease
OBJECTIVE: We examined whether previous inconsistent findings about the effect of anti-Parkinsonian medication on visually-guided saccades (VGS) were due to the use of different paradigms, which change the timing of fixation offset and target onset, or different target eccentricities. METHODS: Thirt...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193957/ https://www.ncbi.nlm.nih.gov/pubmed/35995722 http://dx.doi.org/10.1016/j.clinph.2022.07.505 |
_version_ | 1785043920129884160 |
---|---|
author | Munoz, Miranda J. Reilly, James L. Pal, Gian D. Metman, Leo Verhagen Rivera, Yessenia M. Drane, Quentin H. Corcos, Daniel M. David, Fabian J. Goelz, Lisa C. |
author_facet | Munoz, Miranda J. Reilly, James L. Pal, Gian D. Metman, Leo Verhagen Rivera, Yessenia M. Drane, Quentin H. Corcos, Daniel M. David, Fabian J. Goelz, Lisa C. |
author_sort | Munoz, Miranda J. |
collection | PubMed |
description | OBJECTIVE: We examined whether previous inconsistent findings about the effect of anti-Parkinsonian medication on visually-guided saccades (VGS) were due to the use of different paradigms, which change the timing of fixation offset and target onset, or different target eccentricities. METHODS: Thirty-three participants with Parkinson’s disease (PD) completed the VGS tasks OFF and ON medication, along with 13 healthy controls. Performance on 3 paradigms (gap, step, and overlap) and 2 target eccentricities was recorded. We used mixed models to determine the effect of medication, paradigm, and target eccentricity on saccade latency, gain, and peak velocity. RESULTS: First, we confirmed known paradigm effects on latency, and target eccentricity effects on gain and peak velocity in participants with PD. Second, latency was positively associated with OFF medication Movement Disorders Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) motor score in PD. Third, medication prolonged latency for the larger target eccentricity across the 3 paradigms, while decreasing gain and peak velocity in the step paradigm across target eccentricities. CONCLUSIONS: Medication adversely affected and was not therapeutically beneficial for VGS. Previous inconsistencies may have resulted from chosen target eccentricity. SIGNIFICANCE: The negative medication effect on VGS may be clinically significant, as many activities in daily life require oculomotor control, inhibitory control, and visually-guided shifts of attention. |
format | Online Article Text |
id | pubmed-10193957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-101939572023-05-18 Medication adversely impacts visually-guided eye movements in Parkinson’s disease Munoz, Miranda J. Reilly, James L. Pal, Gian D. Metman, Leo Verhagen Rivera, Yessenia M. Drane, Quentin H. Corcos, Daniel M. David, Fabian J. Goelz, Lisa C. Clin Neurophysiol Article OBJECTIVE: We examined whether previous inconsistent findings about the effect of anti-Parkinsonian medication on visually-guided saccades (VGS) were due to the use of different paradigms, which change the timing of fixation offset and target onset, or different target eccentricities. METHODS: Thirty-three participants with Parkinson’s disease (PD) completed the VGS tasks OFF and ON medication, along with 13 healthy controls. Performance on 3 paradigms (gap, step, and overlap) and 2 target eccentricities was recorded. We used mixed models to determine the effect of medication, paradigm, and target eccentricity on saccade latency, gain, and peak velocity. RESULTS: First, we confirmed known paradigm effects on latency, and target eccentricity effects on gain and peak velocity in participants with PD. Second, latency was positively associated with OFF medication Movement Disorders Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) motor score in PD. Third, medication prolonged latency for the larger target eccentricity across the 3 paradigms, while decreasing gain and peak velocity in the step paradigm across target eccentricities. CONCLUSIONS: Medication adversely affected and was not therapeutically beneficial for VGS. Previous inconsistencies may have resulted from chosen target eccentricity. SIGNIFICANCE: The negative medication effect on VGS may be clinically significant, as many activities in daily life require oculomotor control, inhibitory control, and visually-guided shifts of attention. 2022-11 2022-08-08 /pmc/articles/PMC10193957/ /pubmed/35995722 http://dx.doi.org/10.1016/j.clinph.2022.07.505 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Article Munoz, Miranda J. Reilly, James L. Pal, Gian D. Metman, Leo Verhagen Rivera, Yessenia M. Drane, Quentin H. Corcos, Daniel M. David, Fabian J. Goelz, Lisa C. Medication adversely impacts visually-guided eye movements in Parkinson’s disease |
title | Medication adversely impacts visually-guided eye movements in Parkinson’s disease |
title_full | Medication adversely impacts visually-guided eye movements in Parkinson’s disease |
title_fullStr | Medication adversely impacts visually-guided eye movements in Parkinson’s disease |
title_full_unstemmed | Medication adversely impacts visually-guided eye movements in Parkinson’s disease |
title_short | Medication adversely impacts visually-guided eye movements in Parkinson’s disease |
title_sort | medication adversely impacts visually-guided eye movements in parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193957/ https://www.ncbi.nlm.nih.gov/pubmed/35995722 http://dx.doi.org/10.1016/j.clinph.2022.07.505 |
work_keys_str_mv | AT munozmirandaj medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease AT reillyjamesl medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease AT palgiand medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease AT metmanleoverhagen medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease AT riverayesseniam medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease AT dranequentinh medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease AT corcosdanielm medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease AT davidfabianj medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease AT goelzlisac medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease |